Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Examining the Future: Castle Biosciences's Earnings Outlook

Author: Benzinga Insights | August 01, 2025 02:06pm

Castle Biosciences (NASDAQ:CSTL) is gearing up to announce its quarterly earnings on Monday, 2025-08-04. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Castle Biosciences will report an earnings per share (EPS) of $-0.50.

Investors in Castle Biosciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Earnings History Snapshot

The company's EPS missed by $0.13 in the last quarter, leading to a 11.36% drop in the share price on the following day.

Here's a look at Castle Biosciences's past performance and the resulting price change:

Quarter Q1 2025 Q4 2024 Q3 2024 Q2 2024
EPS Estimate -0.07 0.04 -0.06 -0.29
EPS Actual -0.20 0.32 0.08 0.31
Price Change % -11.0% -14.000000000000002% -7.000000000000001% 14.000000000000002%

eps graph

Stock Performance

Shares of Castle Biosciences were trading at $15.15 as of July 31. Over the last 52-week period, shares are down 32.04%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.

To track all earnings releases for Castle Biosciences visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: CSTL

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist